On Friday, Juul Labs was granted permission by the Food and Drug Administration to market an updated version of its flagship e‑cigarette, according to a report by Matthew Perrone in Washington. The new device incorporates an optional age‑verification system designed to block access by minors, a move that the regulator says satisfies its latest safety criteria for tobacco‑related products.
Juul’s original product line has been under intense scrutiny for its role in the rise of vaping among teenagers, prompting multiple investigations and enforcement actions by the FDA over the past years. The agency has repeatedly warned manufacturers to adopt robust age‑verification mechanisms before approving any new or modified devices, citing public‑health concerns about nicotine exposure in youths.
ALSO READ | Apple’s First Foldable iPhone Duo Set for Tonight’s Launch with Leaked Color Lineup and Pricing
The age‑gating technology embedded in the updated Juul device is not mandatory for retailers but can be activated at the point of sale. When enabled, the system requires a real‑time verification of the buyer’s age through a digital ID check or a government‑issued identification scan, preventing the transaction if the user is under the legal age for tobacco products. Juul describes the feature as “optional” to give retailers flexibility while still offering a tool to deter under‑age purchases.
Industry analysts view the FDA’s approval as a potential turning point for the vaping market, which has struggled with declining sales and heightened regulatory pressure. By integrating a verifiable age‑check, Juul hopes to restore confidence among retailers and consumers, positioning the new model as a responsible alternative that aligns with evolving public‑health expectations.
Juul plans to roll out the updated device across its existing distribution network within the next few weeks, with a focus on markets that have previously restricted its products. The company has indicated that it will work closely with retailers to train staff on the optional verification system and will monitor compliance data submitted to the FDA to ensure the feature effectively reduces under‑age sales.
